URGN · NASDAQ
UroGen Pharma Ltd.
$33.91 -0.13 (-0.38%)
Company overview
UroGen Pharma Ltd. is a biotechnology company focused on developing and commercializing novel solutions for specialty cancers and urothelial diseases. The company offers RTGel, a polymeric biocompatible reverse thermal gelation hydrogel designed to improve the therapeutic profiles of existing drugs, and Jelmyto for pyelocalyceal solution. Its lead product candidate is UGN-102, which is in Phase III clinical trials for treating several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. UroGen is also developing UGN-301 for high-grade non-muscle invasive bladder cancer. The company holds license agreements with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products containing RTGel and clostridial toxins, and with Agenus Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.7B
- Employees
- 234
- Headquarters
- Princeton, NJ
- Website
- urogen.com
- CEO
- Elizabeth A. Barrett
- Listed
- May 4, 2017
- P/E
- -12.33
- Dividend yield
- 0.00%
Company financials
- Revenue
- $140M
- Gross profit
- $126M
- Operating income
- -$108M
- EBITDA
- -$116M
- Net income
- -$133M
- EPS
- -$2.75
- Total assets
- $254M
- Total debt
- $197M
- Gross margin
- 89.85%
- Net margin
- -94.83%
- Earnings yield
- -8.11%
No geographic segmentation.
Showing FY 2025
URGN
1D
NASDAQ
O34.64H35.00L33.87C34.04-0.45 (-1.30%)Vol670.05K